TAPBPL

Across TCGA pan-cancer cohorts, TAPBPL mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated TAPBPL data layer compared with 24 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher TAPBPL mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated TAPBPL expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

CCRCC, PDAC, and LUAD are the cancer types where TAPBPL mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	IV	0.147	0.908	.024	12	view →
PDAC	DFS	Median	III,IV	0.570	0.210	.009	6	view →
LUAD	OS	Quartile	III,IV	0.662	0.994	.030	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

TAPBPL–CCRCC (DFS)

Open the CCRCC breakdown →